POLE and POLD1 encode the catalytic and proofreading subunits of DNA polymerase ε and
polymerase δ, and play important roles in DNA replication and proofreading. POLE/POLD1 …

In less than a decade, half a dozen immune checkpoint inhibitors have been approved and
are currently revolutionising the treatment of many cancer (sub) types. With the clinical …

To date, immunotherapy has opened a new chapter in the treatment of lung cancer. Precise
biomarkers can help to screen subpopulations of lung cancer to provide the best treatment …

The mechanisms governing the methylome profile of tumor suppressors and oncogenes
have expanded with the discovery of oxidized states of 5-methylcytosine (5mC). Ten-eleven …

Background The ten-eleven translocation 1 (TET1) protein is a 5-methylcytosine
hydroxylase that belongs to the TET protein family of human α-ketoglutarate oxygenases …

Immune checkpoint inhibitors (ICIs) have made great progress in the field of tumors and
have become a promising direction of tumor treatment. With advancements in genomics and …

Thymic carcinoma is rare and has a poorer prognosis than thymomas. The treatment options
are limited after failure of platinum-based chemotherapy. We previously performed a single …

The immunosuppressive tumor microenvironment plays an essential role in the treatment of
head and neck squamous cell carcinoma (HNSC). Compared to traditional …

Background A critical and challenging process in immunotherapy is to identify cancer
patients who could benefit from immune checkpoint inhibitors (ICIs). Exploration of predictive …

Background The co-receptor lymphocyte-activation gene-3 (LAG3, LAG-3, CD223) is a
potential target for immune checkpoint inhibition immunotherapies. However, little is known …